Drug Profile
RS 86505 007
Latest Information Update: 17 Nov 2006
Price :
$50
*
At a glance
- Originator Roche Palo Alto LLC
- Class Antihyperlipidaemics; Gastric antisecretories
- Mechanism of Action Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 29 Jul 1998 No-Development-Reported for Hypercholesterolaemia in Finland (PO)
- 08 Sep 1995 Investigation in Hypercholesterolaemia in Finland (PO)